30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 936
- Registration Number
- NCT01183013
- Locations
- 🇺🇸
1264.3.01006 Boehringer Ingelheim Investigational Site, Norwalk, California, United States
🇺🇸1264.3.01044 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States
🇺🇸1264.3.01084 Boehringer Ingelheim Investigational Site, Cartersville, Georgia, United States
Telmisartan, Amlodipine and Combination in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: amlodipine/telmisartan/combination
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT01181011
- Locations
- 🇨🇳
1235.30.86001 Boehringer Ingelheim Investigational Site, Shanghai, China
Tiotropium Bromide in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo Respimat® inhaler
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 464
- Registration Number
- NCT01179347
- Locations
- 🇺🇸
205.438.01019 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States
🇦🇺205.438.61001 Boehringer Ingelheim Investigational Site, Adelaide, South Australia, Australia
🇨🇦205.438.02001 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BI 10773 open labelDrug: Placebo identical to BI10773 low doseDrug: Placebo identical to Sitagliptin 100mgDrug: Placebo identical to BI10773 high dose
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 986
- Registration Number
- NCT01177813
- Locations
- 🇧🇪
1245.20.32016 Boehringer Ingelheim Investigational Site, Deurne, Belgium
🇺🇸1245.20.10154 Boehringer Ingelheim Investigational Site, Chino, California, United States
🇺🇸1245.20.10078 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States
Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 571
- Registration Number
- NCT01174459
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 94, Toyokawa, Japan
🇯🇵Boehringer Ingelheim Investigational Site 151, Kumamoto, Japan
🇯🇵Boehringer Ingelheim Investigational Site 82, Gifu, Japan
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: 50 mcg salmeterol HFA MDI
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1071
- Registration Number
- NCT01172808
- Locations
- 🇧🇷
205.418.55002 Boehringer Ingelheim Investigational Site, Juiz de Fora, Brazil
🇺🇸205.418.01004 Boehringer Ingelheim Investigational Site, Coeur d'Alene, Idaho, United States
🇺🇸205.418.01013 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
- Conditions
- Asthma
- Interventions
- Drug: placeboDrug: 50 mcg salmeterol HFA MDI
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1032
- Registration Number
- NCT01172821
- Locations
- 🇺🇸
205.419.01068 Boehringer Ingelheim Investigational Site, Novi, Michigan, United States
🇺🇸205.419.01071 Boehringer Ingelheim Investigational Site, Raleigh, North Carolina, United States
🇺🇸205.419.01056 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 198
- Registration Number
- NCT01170065
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇨🇱Instituto Nacional del Tórax, Santiago, Chile
🇧🇬Special. Hospital for Active Treatment, Sv. Sofia 2nd Clinic, Sofia, Bulgaria
Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 651
- Registration Number
- NCT01170091
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site 1, Busan, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 2, Busan, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 35, Daejeon, Korea, Republic of
Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT01170637
- Locations
- 🇩🇪
1024.7.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany